Report

reporttype1Version of Safety Report ID1receivedateformat102transmissiondateformat102fulfillexpeditecriteria1Safety Report ID10166458serious1Date Last Updated12/05/2014receiptdateformat102companynumbAU-ELI_LILLY_AND_COMPANY-AU201404010013occurcountryAUseriousnessother1duplicate1Date Received12/05/2014transmissiondate12/12/2014primarysourcecountryAU

Primary Source

reportercountryAUqualification5

Patient

SexMale

Reaction

1)

reactionmeddraversionpt17.0ReactionSerotonin syndromeOutcomeUnknown

2)

reactionmeddraversionpt17.0ReactionPyrexiaOutcomeUnknown

3)

reactionmeddraversionpt17.0ReactionIncreased upper airway secretionOutcomeUnknown

4)

reactionmeddraversionpt17.0ReactionHypothermiaOutcomeUnknown

5)

reactionmeddraversionpt17.0ReactionDizzinessOutcomeUnknown

6)

reactionmeddraversionpt17.0ReactionParaesthesiaOutcomeUnknown

7)

reactionmeddraversionpt17.0ReactionTinnitusOutcomeUnknown

8)

reactionmeddraversionpt17.0ReactionConfusional stateOutcomeUnknown

9)

reactionmeddraversionpt17.0ReactionAstheniaOutcomeUnknown

10)

reactionmeddraversionpt17.0ReactionPollakiuriaOutcomeUnknown

Drug

1)

drugcharacterization1medicinalproductCYMBALTAdrugstructuredosagenumb1drugstructuredosageunit032drugdosagetextUNK, UNKNOWNdrugdosageformCAPSULEdrugadministrationroute065drugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5drugrecurreadministration3

openFDA Info on Medication

Application NumberNDA021427Brand NameCYMBALTAGeneric NameDULOXETINE HYDROCHLORIDEManufacturersEli Lilly and Companyproduct_ndc0002-3235, 0002-3240, 0002-3270Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsDULOXETINE HYDROCHLORIDERXCUI596926, 596928, 596930, 596932, 596934, 615186spl_idb742d0a5-e67d-49ed-ba95-afe068f1d228spl_set_id2f7d4d67-10c1-4bf4-a7f2-c185fbad64baPackage NDC0002-3235-60, 0002-3240-30, 0002-3240-90, 0002-3270-30, 0002-3270-04UNII9044SC542W

2)

drugcharacterization1medicinalproductZYPREXAdrugauthorizationnumb020592drugstructuredosagenumb1drugstructuredosageunit032drugdosagetextUNK, UNKNOWNdrugadministrationroute065drugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5drugrecurreadministration3

openFDA Info on Medication

Application NumberNDA020592, NDA021086, NDA021253, NDA022173Brand NameZYPREXA, ZYPREXA ZYDIS, ZYPREXA INTRAMUSCULAR, ZYPREXA RELPREVVGeneric NameOLANZAPINE, OLANZAPINE PAMOATEManufacturersEli Lilly and Companyproduct_ndc 0002-4112, 0002-4115, 0002-4116, 0002-4117, 0002-4415, 0002-4420, 0002-4453, 000 ... Product TypeHUMAN PRESCRIPTION DRUGRouteORAL, INTRAMUSCULARActive IngredientsOLANZAPINERXCUI 153046, 153047, 153048, 200034, 212405, 261337, 283639, 284514, 312076, 312077, ... spl_idab87dd62-b7a0-4b0c-92e3-a14eac38b76e, 1510c949-be2b-4de1-a10a-edb597fe51e2spl_set_idd5051fbc-846b-4946-82df-341fb1216341, f9a73185-88de-4d7b-b3c0-bbf231483241Package NDC 0002-4112-30, 0002-4115-30, 0002-4116-30, 0002-4117-30, 0002-4415-30, 0002-4420- ... NUIN0000175430Established Pharmacologic ClassAtypical Antipsychotic [EPC]UNIIN7U69T4SZR

3)

drugcharacterization1medicinalproductAROPAXdrugstructuredosagenumb1drugstructuredosageunit032drugdosagetextUNK, UNKNOWNdrugadministrationroute065drugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5drugrecurreadministration3

4)

drugcharacterization1medicinalproductCELEBREXdrugstructuredosagenumb1drugstructuredosageunit032drugdosagetextUNK, UNKNOWNdrugadministrationroute065drugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5drugrecurreadministration3

openFDA Info on Medication

Application NumberNDA020998Brand NameCELEBREXGeneric NameCELECOXIBManufacturersG.D. Searle LLC Division of Pfizer Incproduct_ndc0025-1515, 0025-1520, 0025-1525, 0025-1530Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsCELECOXIBRXCUI205322, 205323, 213468, 213469, 349514, 352314, 686379, 686381spl_idd2a1146b-f1a6-4467-9ba8-b10f94494f8espl_set_id8d52185d-421f-4e34-8db7-f7676db2a226Package NDC 0025-1515-01, 0025-1520-31, 0025-1520-51, 0025-1520-34, 0025-1525-31, 0025-1525- ... NUIN0000000160, M0001335, N0000175722Mechanism of ActionCyclooxygenase Inhibitors [MoA]Chemical StructureAnti-Inflammatory Agents, Non-Steroidal [CS]Established Pharmacologic ClassNonsteroidal Anti-inflammatory Drug [EPC]UNIIJCX84Q7J1L

5)

drugcharacterization1medicinalproductCIPRAMIL /00582602/drugstructuredosagenumb1drugstructuredosageunit032drugdosagetextUNK, UNKNOWNdrugadministrationroute065drugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5drugrecurreadministration3

6)

drugcharacterization1medicinalproductEFEXORdrugstructuredosagenumb1drugstructuredosageunit032drugdosagetextUNK, UNKNOWNdrugadministrationroute065drugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5drugrecurreadministration3

7)

drugcharacterization1medicinalproductENDEPdrugstructuredosagenumb1drugstructuredosageunit032drugdosagetextUNK, UNKNOWNdrugadministrationroute065drugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5drugrecurreadministration3

8)

drugcharacterization1medicinalproductENDONEdrugstructuredosagenumb1drugstructuredosageunit032drugdosagetextUNK, UNKNOWNdrugadministrationroute065drugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5drugrecurreadministration3

9)

drugcharacterization1medicinalproductLEXAPROdrugstructuredosagenumb1drugstructuredosageunit032drugdosagetextUNK, UNKNOWNdrugadministrationroute065drugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5drugrecurreadministration3

openFDA Info on Medication

Application NumberNDA021323Brand NameLEXAPROGeneric NameESCITALOPRAM OXALATEManufacturersAllergan, Inc.product_ndc0456-2005, 0456-2010, 0456-2020, 0456-2101Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsESCITALOPRAM OXALATERXCUI349332, 351249, 351250, 351285, 352272, 352273, 404408, 404420spl_idf7659260-4527-4446-9aa5-15a2895c5b0espl_set_id13bb8267-1cab-43e5-acae-55a4d957630aPackage NDC 0456-2005-01, 0456-2010-01, 0456-2010-11, 0456-2010-63, 0456-2020-01, 0456-2020- ... UNII5U85DBW7LO

10)

drugcharacterization1medicinalproductMOGADONdrugstructuredosagenumb1drugstructuredosageunit032drugdosagetextUNK, UNKNOWNdrugadministrationroute065drugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5drugrecurreadministration3

11)

drugcharacterization1medicinalproductNAPROXENdrugstructuredosagenumb1drugstructuredosageunit032drugdosagetextUNK, UNKNOWNdrugadministrationroute065drugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5drugrecurreadministration3

openFDA Info on Medication

Application Number ANDA091416, NDA018965, ANDA204872, ANDA091432, ANDA075927, ANDA091305, ANDA21270 ... Brand NameNAPROXEN, NAPROSYN, BACK AND MUSCLE PAIN, EC-NAPROXEN, EC-NAPROSYNGeneric NameNAPROXEN, NAPROXEN SODIUMManufacturers MARKSANS PHARMA LIMITED, Allegis Holdings, LLC, Amerisource Bergen, Virtus Pharm ... product_ndc 25000-138, 25000-139, 25000-140, 71297-200, 46122-564, 69543-425, 69543-426, 461 ... Product TypeHUMAN PRESCRIPTION DRUG, HUMAN OTC DRUGRouteORALActive IngredientsNAPROXEN, NAPROXEN SODIUMRXCUI 198012, 198013, 198014, 311913, 849574, 311915, 603103, 207093, 849398, 849431, ... spl_id 6fa09e97-8e2d-4d74-9490-3eb2169820f6, b61f4f8a-87e2-3fa6-e053-2995a90a0b2e, 7543 ... spl_set_id 1fdb4cbd-e9e8-47bb-b3d8-1f1ec8f411c8, bc979c90-5853-4a95-8402-ba6b57100b17, 1e2e ... Package NDC 25000-138-03, 25000-138-14, 25000-138-21, 25000-138-31, 25000-138-98, 25000-139- ... NUIN0000000160, M0001335, N0000175722Mechanism of ActionCyclooxygenase Inhibitors [MoA]Chemical StructureAnti-Inflammatory Agents, Non-Steroidal [CS]Established Pharmacologic ClassNonsteroidal Anti-inflammatory Drug [EPC]UNII57Y76R9ATQ, 9TN87S3A3C

12)

drugcharacterization1medicinalproductOXYCONTINdrugstructuredosagenumb1drugstructuredosageunit032drugdosagetextUNK, UNKNOWNdrugadministrationroute065drugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5drugrecurreadministration3

openFDA Info on Medication

Application NumberNDA022272Brand NameOXYCONTINGeneric NameOXYCODONE HYDROCHLORIDEManufacturersPurdue Pharma LPproduct_ndc59011-410, 59011-480, 59011-415, 59011-420, 59011-430, 59011-440, 59011-460Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsOXYCODONE HYDROCHLORIDERXCUI 1049504, 1049545, 1049565, 1049576, 1049586, 1049595, 1049601, 1860127, 1860129, ... spl_id21ec1aed-af99-6d71-bc44-4755651ecd9espl_set_idbfdfe235-d717-4855-a3c8-a13d26dadedePackage NDC 59011-480-20, 59011-480-10, 59011-410-10, 59011-410-20, 59011-415-10, 59011-415- ... UNIIC1ENJ2TE6C

13)

drugcharacterization1medicinalproductPANADEINE /00116401/drugstructuredosagenumb1drugstructuredosageunit032drugdosagetextUNK, UNKNOWNdrugadministrationroute065drugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5drugrecurreadministration3

14)

drugcharacterization1medicinalproductSEREPAXdrugstructuredosagenumb1drugstructuredosageunit032drugdosagetextUNK, UNKNOWNdrugadministrationroute065drugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5drugrecurreadministration3

15)

drugcharacterization1medicinalproductVALIUM /00017001/drugstructuredosagenumb1drugstructuredosageunit032drugdosagetextUNK, UNKNOWNdrugadministrationroute065drugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5drugrecurreadministration3

16)

drugcharacterization1medicinalproductZOLOFTdrugstructuredosagenumb1drugstructuredosageunit032drugdosagetextUNK, UNKNOWNdrugadministrationroute065drugindicationPRODUCT USED FOR UNKNOWN INDICATIONactiondrug5drugrecurreadministration3

openFDA Info on Medication

Application NumberNDA020990, NDA019839Brand NameZOLOFTGeneric NameSERTRALINE HYDROCHLORIDEManufacturersRoerigproduct_ndc0049-0050, 0049-4960, 0049-4900, 0049-4910Product TypeHUMAN PRESCRIPTION DRUGRouteORALActive IngredientsSERTRALINE HYDROCHLORIDERXCUI208149, 208161, 212233, 312938, 312940, 312941, 861064, 861066spl_id665a145d-44fb-4fef-a3c1-2aac26e0715cspl_set_idfe9e8b7d-61ea-409d-84aa-3ebd79a046b5Package NDC 0049-4960-30, 0049-4960-50, 0049-4900-30, 0049-4900-66, 0049-4900-73, 0049-4900- ... UNIIUTI8907Y6X

Report Duplicate

duplicatesourceELI LILLY AND COduplicatenumbAU-ELI_LILLY_AND_COMPANY-AU201404010013

Receiver

receivertype6receiverorganizationFDA

Sender

sendertype2senderorganizationFDA-Public Use

Adverse Event Report

Report

Primary Source

Patient

Reaction

1)

2)

3)

4)

5)

6)

7)

8)

9)

10)

Drug

1)

openFDA Info on Medication

2)

openFDA Info on Medication

3)

4)

openFDA Info on Medication

5)

6)

7)

8)

9)

openFDA Info on Medication

10)

11)

openFDA Info on Medication

12)

openFDA Info on Medication

13)

14)

15)

16)

openFDA Info on Medication

Report Duplicate

Receiver

Sender

Media

Newsletter

Follow us

Connect with us